WHY IT MATTERS: If endocannabinoid-targeted pharmaceuticals like these gain FDA approval, patients dealing with cancer-related weight loss and chemotherapy nerve pain could eventually have insurance-covered, standardized treatment options that work through the same system cannabis does. CLINICAL OVERVIEW: Artelo Biosciences is advancing pharmaceutical candidates that target the endocannabinoid system, including ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy. These drug development programs represent a growing trend of biotech companies working to create FDA-approvable medications that modulate endocannabinoid pathways rather than relying solely on plant-derived cannabinoids.
CBD and Liver Enzymes: What the New JAMA Study Actually Shows
A new peer-reviewed study sent ripples through the CBD world—but what does it actually say about liver health? Spoiler: it’s not as simple as “CBD is dangerous.” When you zoom in on the details, the real story is about dose, data, and the difference between panic and perspective.
5 Surprising Benefits of Cannabidiol Anxiety Treatment
Exploring the Benefits and Safety of Nano-particle CBD for Anxiety Treatment What is this All About? Anxiety disorders are some of the most common mental health issues around the world. In 2019,...